Jubilant Pharmova Ltd
JUBLPHARMA (NSE)

344.75

5,487.52
Proj. ROE (%)
7.28
Proj. P/E (x)
12.67
Proj EV / EBITDA (x)
4.88
Proj. P/BV (x)
0.94
Proj. Revenue ( Cr.)
6,193.15

Stock View

BUY
Share on
The average score for Jubilant Pharmova Ltd stands at 3 against 6, three months back.

Jubilant Pharmova Limited is an integrated global pharmaceutical and life sciences company. The Company's segments include Pharmaceuticals, Contract Research and Development Services and Proprietary Novel Drugs. The Pharmaceuticals segment, through wholly owned subsidiary Jubilant Pharma Limited, is engaged in manufacture and supply of active pharmaceutical ingredients (APIs), solid dosage formulations, radiopharmaceuticals, allergy therapy products and contract manufacturing of sterile injectables and non-sterile products through six manufacturing facilities in India, United States and Canada and a network of approximately 48 radio pharmacies in the United States. The Contract Research and Development Services segment provides drug discovery and development services as well as clinical data software and service solutions. The Proprietary Novel Drugs segment is a patient-focused biopharmaceutical business working to address unmet medical needs in oncology and autoimmune diseases.

Disclaimer : All estimates (1 year forward) are based on Consensus View provided by Refinitiv.

Technical Data
50 DMA()
390.37
100 DMA ()
412.70
200 DMA ()
501.61
52 Weeks Range
281.80
767.00
Street View :-
Bearish
Open ZERO Brokerage Demat Account
Open Demat Account

  • 0

    Per Order for ETF & Mutual Funds Brokerage

  • 20

    Per Order for Delivery, Intraday, F&O, Currency & Commodity